Drug firm Sanofi India Ltd delivered exceptional fourth quarter results with profit after tax rising 50% to ₹66.5 crore for the quarter ended December 31, 2025. According to reports from CNBC TV18, the company posted revenue of ₹251 crore, representing a growth of 47% year-on-year. Domestic sales grew 23%, aided by the relaunch of recalled products, while export sales surged 9.3 times due to a low base effect.
The board of directors recommended a final dividend of ₹48 per equity share of face value ₹10 for the financial year ended December 31, 2025. As reported by CNBC TV18, this final dividend is subject to shareholder approval at the 70th annual general meeting and is in addition to the interim dividend of ₹75 per share declared on October 29, 2025. The total dividend for 2025 will amount to ₹123 per equity share.
For the full year 2025, Sanofi Consumer Healthcare India reported revenue of ₹878.4 crore, up 21% from the previous year. According to the company announcement, domestic sales increased 7% and export sales rose 158% on a low base. Profit after tax for the year stood at ₹240.1 crore, up 33% year-on-year, supported by disciplined cost management and an improved product mix.
The board approved significant changes in its leadership structure. As reported by CNBC TV18, Rajani Kesari has been appointed as an additional and independent director for a term of five years, effective April 1, 2026, subject to shareholder approval. Rodolfo Hrosz has tendered his resignation as non-executive director effective February 28, 2026, due to other commitments, with the board recording appreciation for his contributions. Sudipta Chakraborty has been appointed as an additional director and whole-time director for a term of three years, effective March 1, 2026.
Shares of Sanofi India Ltd ended at ₹4,142.80, up by ₹65.20, or 1.60%, on the BSE on February 25, 2026, according to CNBC TV18. The positive market response reflects investor confidence in the company's strong quarterly performance and dividend declaration.
